Industry Overview

Canada myocardial infarction market was valued at approximately $138.4 million in 2025 and is projected to reach around $211.0 million by 2035, expanding at a CAGR of 4.4% during 2026–2035. Myocardial infarction (heart attack) remains a major public health concern, driven by the rising prevalence of cardiovascular diseases and lifestyle-related risk factors. According to the World Health Organization (WHO), cardiovascular diseases account for nearly 32% of global deaths, with ischemic heart disease being the leading cause. In Canada, data from the OECD highlights a high burden of cardiovascular conditions due to aging populations and increasing obesity rates. The market growth is primarily driven by advancements in treatment procedures such as PCI and CABG, along with innovations in diagnostic technologies including ECG and biomarker testing. Additionally, increasing healthcare expenditure and strong government support for cardiovascular disease management are accelerating market expansion.

Major end-use industries include hospitals, cardiac care centers, and ambulatory surgical centers. The integration of minimally invasive procedures and digital health technologies is further enhancing treatment outcomes and driving market growth.

Market Dynamics

Rising Cardiovascular Disease Burden Driving Market Growth

The increasing prevalence of cardiovascular diseases is a key driver of the Canada myocardial infarction market. According to the World Health Organization (WHO), ischemic heart disease remains the leading cause of mortality worldwide, contributing significantly to healthcare demand. In Canada, changing lifestyles, including sedentary behavior and unhealthy diets, have led to a rise in obesity and diabetes, which are major risk factors for myocardial infarction. The OECD reports that healthcare spending on cardiovascular diseases continues to increase, reflecting the growing burden on healthcare systems. Pharmaceutical and medical device companies are actively investing in research and development to introduce advanced therapies and minimally invasive treatment options. Between 2025 and 2026, companies are focusing on clinical trials, product launches, and strategic partnerships to improve treatment outcomes and expand their market presence.

High Treatment Costs and Clinical Complexity Limiting Market Growth

Despite steady growth, the Canada myocardial infarction market faces challenges due to high treatment costs and clinical complexities. Advanced procedures such as PCI and CABG require specialized infrastructure and skilled professionals, leading to increased healthcare expenditure. According to the OECD, rising healthcare costs remain a significant concern across developed economies, including Canada. Additionally, supply chain disruptions and increasing costs of medical devices and pharmaceuticals have impacted market dynamics. Patient variability, including age, comorbidities, and severity of disease, further complicates treatment outcomes. These factors make standardized treatment approaches challenging and increase the risk of complications. To address these issues, companies are focusing on cost-effective solutions, digital health integration, and improved clinical protocols. Innovations such as AI-driven diagnostics and remote monitoring are expected to enhance efficiency and reduce long-term costs.

Market Segmentation

• Based on the treatment type, the market is segmented into pharmacological treatment, interventional procedures, adjunct & supportive care.
• Based on the medical device type, the market is segmented into left ventricular assist device, pacemaker, catheters, implantable cardioverter defibrillator, and others.
• Based on the end-user, the market is segmented into public hospitals, private hospitals, cardiac specialty centers, and ambulatory surgical centers.

Rhythm Control Devices Leading Revenue Share

Pacemakers remain the largest revenue contributor within cardiac device categories, supported by their extensive clinical adoption across myocardial infarction–linked arrhythmia management pathways. Medtronic, Abbott Laboratories, and Boston Scientific continue to dominate through broad product portfolios and global distribution reach. The segment benefits from a high procedural volume, particularly among aging populations, where implantation rates rise sharply with cardiovascular risk exposure. Sustained demand is also tied to the growing burden of rhythm disorders and post-infarction complications, which has driven pacemakers to capture a leading share of device revenues globally. Recent developments reflect a shift toward miniaturized and leadless systems, improving patient compliance and reducing procedural risks. Integration with remote monitoring platforms is enhancing long-term disease management and hospital workflow efficiency. Manufacturers are also investing in battery longevity and MRI-compatible designs to strengthen product differentiation in mature markets.

Defibrillator Systems Gaining Strong Momentum

Implantable cardioverter defibrillators are emerging as one of the fastest expanding segments due to their critical role in preventing sudden cardiac death following myocardial infarction. Clinical reliance on these systems is increasing as survival rates improve and long-term cardiac risk management becomes more structured. Growth is underpinned by rising incidence of high-risk cardiac conditions alongside broader screening and diagnosis capabilities. Key participants such as BIOTRONIK, MicroPort Scientific, and LivaNova are expanding portfolios with advanced sensing and shock-delivery technologies. Technology upgrades are increasingly focused on subcutaneous systems that reduce invasive complexity while maintaining therapeutic efficacy. The segment is also benefiting from innovation in AI-enabled rhythm detection and predictive analytics, improving intervention timing. With cardiovascular device markets expanding steadily above mid-single-digit growth rates, defibrillators are positioned as a high-growth subsegment within the broader treatment ecosystem.

Competitive Landscape

Canada myocardial infarction market is highly competitive, driven by continuous innovation in cardiovascular therapies and medical devices. Key players such as Pfizer Inc., AstraZeneca, Abbott Laboratories, Medtronic, and Bayer AG are focusing on product innovation and expanding their cardiovascular portfolios. Companies are investing in advanced treatment options, including minimally invasive procedures and targeted drug therapies, to improve patient outcomes. Strategic collaborations, clinical trials, and regulatory approvals are key strategies adopted between 2024 and 2026. Additionally, the integration of digital health technologies and AI-driven diagnostics is enhancing disease management. These factors are intensifying competition and driving growth in the market.

Recent Developments

• In April 2026, CorFlow Therapeutics AG reported key progress in its clinical program, including the successful completion of Phase 1 of the MOCA II FDA pivotal trial and the initiation of Phase 2 patient enrollment. The Phase 1 study, conducted across sites in the US and Europe, met safety and performance benchmarks in STEMI heart attack patients by validating its proprietary PCoFI diagnostic method for detecting microvascular obstruction during stenting procedures, with results aligned to cardiac MRI standards.

• In November 2024, Novo Nordisk announced that Health Canada approved Wegovy (semaglutide) for reducing the risk of non-fatal myocardial infarction in adults with cardiovascular disease and obesity. This development represents a major shift toward preventive cardiology by targeting underlying cardiometabolic risk factors rather than only acute treatment.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the Canada myocardial infarction market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.